Lonza helps biotech firms accelerate from DNA to IND with tailored strategies that reduce risk and speed complex biologics to ...
Sac-TMT combined with Keytruda significantly improves progression-free survival in PD-L1-positive advanced non-small cell ...
Biomarker Testing: Pushing the Limits of Ultrasensitivity, Upcoming Webinar Hosted by Xtalks ...
Artios Pharma collected $115 million from an oversubscribed series D that will support its growing ambitions for its pipeline ...
News-Medical.Net on MSN
Tiny antibiotic traces found to greatly accelerate resistance spread
Antibiotic resistance is widely recognized as one of the most urgent public health challenges of the twenty first century.
On5, 2025, Clinical study results from Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech", HKEX: 6990)'s TROP2 ADC sacituzumab tirumotecan (sac-TMT) monotherapy for advanced or ...
Rhabdomyosarcoma Market is Expected to Rise Throughout Forecast Period (2025-2034) with Promising Drug Candidates in Pipeline | DelveInsight ...
Artios Pharma has successfully closed an oversubscribed $115million Series D financing round co-led by founding investor SV ...
Artios Pharma, which looking for newer targets that, like PARP inhibitors, affect the way tumors fix themselves, said its ...
Highlighting 10 innovative late-stage BioPharma drugs with the potential to reshape treatment paradigms and industry dynamics ...
Artios has closed an oversubscribed $115 million series D to accelerate development of its DNA damage response pipeline, ...
Funding advances Phase 2 expansion cohorts in pancreatic and colorectal cancer in ATM-negative patients for Artios’ potential first-in-class ATR Inhibitor, alnodesertib Following encouraging ESMO data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback